RE-DUAL PCI was an international, multicenter, randomized open-label trial of 2725 patients with nonvalvular AF who had undergone PCI with stenting. Patients were randomized to receive 1 of 3 treatments: double therapy with dabigatran (110 mg twice daily) plus either clopidogrel or ticagrelor (110-mg dual-therapy group), double therapy with dabigatran (150 mg twice daily) plus either clopidogrel or ticagrelor (150-mg dual- therapy group), or triple therapy with warfarin plus aspirin ( 100 mg daily) and either clopido- grel or ticagrelor (triple-therapy group). The inci- dence of major or clinically relevant nonmajor bleeding was higher in the triple-therapy group than in the 110-mg dual-therapy group and the 150-mg dual-therapy group. In addition, the 2 dual-therapy groups combined were noninferior to the triple-therapy group with regard to the composite efficacy endpoint of thromboembolic events (MI, stroke, or systemic embolism), death, or unplanned revascularization. Clopidogrel was the most common P2Y12 inhibitor used (88%). Notably, the study was not powered to evaluate risk of stent thrombosis or systemic In aggregate, the data to date on compari- sons of double versus triple therapy demonstrate that double therapy significantly reduces the risk of bleeding without a signal of harm with re- gard to stent thrombosis in clinical trials that en- rolled both patients with stable ischemic disease and patients with ACS. 